|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng L, Luo S, Jin C, Ma H, Zhou H and
Jia L: FUT family mediates the multidrug resistance of human
hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell
Death Dis. 4:e9232013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marin JJ, Monte MJ, Blazquez AG, Macias
RI, Serrano MA and Briz O: The role of reduced intracellular
concentrations of active drugs in the lack of response to
anticancer chemotherapy. Acta Pharmacol Sin. 35:1–10. 2014.
View Article : Google Scholar :
|
|
6
|
Dean M, Hamon Y and Chimini G: The human
ATP-binding cassette (ABC) transporter superfamily. J Lipid Res.
42:1007–1017. 2001.PubMed/NCBI
|
|
7
|
Hagmann W, Jesnowski R, Faissner R, Guo C
and Löhr JM: ATP-binding cassette C transporters in human
pancreatic carcinoma cell lines. Upregulation in
5-fluorouracil-resistant cells. Pancreatology. 9:136–144. 2009.
View Article : Google Scholar
|
|
8
|
Nambaru PK, Hübner T, Köck K, Mews S,
Grube M, Payen L, Guitton J, Sendler M, Jedlitschky G, Rimmbach C,
et al: Drug efflux transporter multidrug resistance-associated
protein 5 affects sensitivity of pancreatic cancer cell lines to
the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos.
39:132–139. 2011. View Article : Google Scholar
|
|
9
|
Hagmann W, Faissner R, Schnölzer M, Löhr M
and Jesnowski R: Membrane drug transporters and chemoresistance in
human pancreatic carcinoma. Cancers. 3:106–125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hlavata I, Mohelnikova-Duchonova B,
Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O,
Holubec L, Treska V, et al: The role of ABC transporters in
progression and clinical outcome of colorectal cancer. Mutagenesis.
27:187–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Long J, Zhang Y, Yu X, Yang J, LeBrun DG,
Chen C, Yao Q and Li M: Overcoming drug resistance in pancreatic
cancer. Expert Opin Ther Targets. 15:817–828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang WB, Yang Y, Zhao YP, Zhang TP, Liao Q
and Shu H: Recent studies of 5-fluorouracil resistance in
pancreatic cancer. World J Gastroenterol. 20:15682–15690. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW,
Lee Y, Chon CY, Moon YM and Han KH: Repetitive short-course hepatic
arterial infusion chemotherapy with high-dose 5-fluorouracil and
cisplatin in patients with advanced hepatocellular carcinoma.
Cancer. 110:129–137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma MC, Chen YY, Li SH, Cheng YF, Wang CC,
Chiu TJ, Pei SN, Liu CT, Huang TL, Huang CH, et al: Intra-arterial
chemotherapy with doxorubicin and cisplatin is effective for
advanced hepatocellular cell carcinoma. Scientific World Journal.
2014:1601382014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Johnson PJ: Are there indications for
chemotherapy in hepatocellular carcinoma? Surg Oncol Clin N Am.
12:127–134. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nishimura M: A successful treatment by
hepatic arterial infusion therapy for advanced, unresectable
biliary tract cancer. World J Hepatol. 2:192–197. 2010.PubMed/NCBI
|
|
17
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kowalski P, Surowiak P and Lage H:
Reversal of different drug-resistant phenotypes by an autocatalytic
multitarget multiribozyme directed against the transcripts of the
ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther. 11:508–522.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kuwano M, Toh S, Uchiumi T, Takano H,
Kohno K and Wada M: Multidrug resistance-associated protein
subfamily transporters and drug resistance. Anticancer Drug Des.
14:123–131. 1999.PubMed/NCBI
|
|
20
|
Materna V, Holm PS, Dietel M and Lage H:
Kinetic characterization of ribozymes directed against the
cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2.
Cancer Gene Ther. 8:176–184. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li QL, Ito K, Sakakura C, Fukamachi H,
Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, et al: Causal
relationship between the loss of RUNX3 expression and gastric
cancer. Cell. 109:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Subramaniam MM, Chan JY, Yeoh KG, Quek T,
Ito K and Salto-Tellez M: Molecular pathology of RUNX3 in human
carcinogenesis. Biochim Biophys Acta. 1796:315–331. 2009.PubMed/NCBI
|
|
23
|
Nakanishi Y, Shiraha H, Nishina S, Tanaka
S, Matsubara M, Horiguchi S, Iwamuro M, Takaoka N, Uemura M, Kuwaki
K, et al: Loss of runt-related transcription factor 3 expression
leads hepatocellular carcinoma cells to escape apoptosis. BMC
Cancer. 11:32011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishina S, Shiraha H, Nakanishi Y, Tanaka
S, Matsubara M, Takaoka N, Uemura M, Horiguchi S, Kataoka J,
Iwamuro M, et al: Restored expression of the tumor suppressor gene
RUNX3 reduces cancer stem cells in hepatocellular carcinoma by
suppressing Jagged1-Notch signaling. Oncol Rep. 26:523–531.
2011.PubMed/NCBI
|
|
25
|
Tanaka S, Shiraha H, Nakanishi Y, Nishina
S, Matsubara M, Horiguchi S, Takaoka N, Iwamuro M, Kataoka J,
Kuwaki K, et al: Runt-related transcription factor 3 reverses
epithelial-mesenchymal transition in hepatocellular carcinoma. Int
J Cancer. 131:2537–2546. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horiguchi S, Shiraha H, Nagahara T,
Kataoka J, Iwamuro M, Matsubara M, Nishina S, Kato H, Takaki A,
Nouso K, et al: Loss of runt-related transcription factor 3 induces
gemcitabine resistance in pancreatic cancer. Mol Oncol. 7:840–849.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mori T, Nomoto S, Koshikawa K, Fujii T,
Sakai M, Nishikawa Y, Inoue S, Takeda S, Kaneko T and Nakao A:
Decreased expression and frequent allelic inactivation of the RUNX3
gene at 1p36 in human hepatocellular carcinoma. Liver Int.
25:380–388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiao WH and Liu WW: Hemizygous deletion
and hypermethylation of RUNX3 gene in hepatocellular carcinoma.
World J Gastroenterol. 10:376–380. 2004.PubMed/NCBI
|
|
29
|
Li X, Zhang Y, Zhang Y, Qiao T, Wu K, Ding
J, Liu J and Fan D: RUNX3 inhibits growth of HCC cells and HCC
xenografts in mice in combination with adriamycin. Cancer Biol
Ther. 7:669–676. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo C, Ding J, Yao L, Sun L, Lin T, Song
Y, Sun L and Fan D: Tumor suppressor gene Runx3 sensitizes gastric
cancer cells to chemotherapeutic drugs by downregulating Bcl-2,
MDR-1 and MRP-1. Int J Cancer. 116:155–160. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu F, Hou YQ, Song Y and Yuan ZJ: TFPI-2
downregulates multidrug resistance protein in 5-FU-resistant human
hepatocellular carcinoma BEL-7402/5-FU cells. Anat Rec. 296:56–63.
2013. View
Article : Google Scholar
|
|
32
|
Gu W, Fang FF, Li B, Cheng BB and Ling CQ:
Characterization and resistance mechanisms of a
5-fluorouracil-resistant hepatocellular carcinoma cell line. Asian
Pac J Cancer Prev. 13:4807–4814. 2012. View Article : Google Scholar
|
|
33
|
Zisowsky J, Koegel S, Leyers S,
Devarakonda K, Kassack MU, Osmak M and Jaehde U: Relevance of drug
uptake and efflux for cisplatin sensitivity of tumor cells. Biochem
Pharmacol. 73:298–307. 2007. View Article : Google Scholar
|
|
34
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Samimi G, Katano K, Holzer AK, Safaei R
and Howell SB: Modulation of the cellular pharmacology of cisplatin
and its analogs by the copper exporters ATP7A and ATP7B. Mol
Pharmacol. 66:25–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
